“You’ve got to breathe, you know” – asthma patients and carers’ perceptions around purchase and use of asthma preventer medicines

Sharon R. Davis, Jacqueline Tudball, Anthony Flynn, Kirsty Lembke, Nicholas Zwar, Helen K. Reddel

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Objective: To explore influences on patients’ purchase and use of asthma preventer medicines and the perceived acceptability of financial incentives via reduced patient co-payments. Methods: Semi-structured telephone or face-to-face interviews were conducted with adults and carers of children with asthma. Interviews were recorded, transcribed verbatim and coded. Data were analysed using thematic analysis via grounded theory. Results: Twenty-four adults and 20 carers for children aged 3–17 years with asthma were interviewed. For medicines choice, most participants did not consider themselves the primary decision-maker; cost of medicines was an issue for some, but effectiveness was described as more important. For adherence, cost, side-effects, perceived benefit and patient behaviours were important. Conclusions: Patient barriers to adherence with asthma preventer medicines including cost are ongoing. Healthcare professionals need to encourage empathic discussion with patients about cost issues. Implications for public health: Asthma patients and carers could benefit from greater involvement and respect within shared decision-making. Healthcare professionals should be aware that cost may be a barrier for patient adherence, and provided with information about the relative costs of guideline-recommended asthma medicines. Patients and healthcare professionals need education around the efficacy of ICS-alone treatment and the rationale behind co-payments, for initiatives around quality use of medicines to succeed.

Original languageEnglish
JournalAustralian and New Zealand Journal of Public Health
DOIs
Publication statusE-pub ahead of print - 6 Feb 2019
Externally publishedYes

Fingerprint

Caregivers
Asthma
Costs and Cost Analysis
Delivery of Health Care
Interviews
Professional Education
Patient Compliance
Telephone
Motivation
Decision Making
Public Health
Guidelines

Cite this

@article{3406eb85cd274eb9b4749e6e9f177a07,
title = "“You’ve got to breathe, you know” – asthma patients and carers’ perceptions around purchase and use of asthma preventer medicines",
abstract = "Objective: To explore influences on patients’ purchase and use of asthma preventer medicines and the perceived acceptability of financial incentives via reduced patient co-payments. Methods: Semi-structured telephone or face-to-face interviews were conducted with adults and carers of children with asthma. Interviews were recorded, transcribed verbatim and coded. Data were analysed using thematic analysis via grounded theory. Results: Twenty-four adults and 20 carers for children aged 3–17 years with asthma were interviewed. For medicines choice, most participants did not consider themselves the primary decision-maker; cost of medicines was an issue for some, but effectiveness was described as more important. For adherence, cost, side-effects, perceived benefit and patient behaviours were important. Conclusions: Patient barriers to adherence with asthma preventer medicines including cost are ongoing. Healthcare professionals need to encourage empathic discussion with patients about cost issues. Implications for public health: Asthma patients and carers could benefit from greater involvement and respect within shared decision-making. Healthcare professionals should be aware that cost may be a barrier for patient adherence, and provided with information about the relative costs of guideline-recommended asthma medicines. Patients and healthcare professionals need education around the efficacy of ICS-alone treatment and the rationale behind co-payments, for initiatives around quality use of medicines to succeed.",
author = "Davis, {Sharon R.} and Jacqueline Tudball and Anthony Flynn and Kirsty Lembke and Nicholas Zwar and Reddel, {Helen K.}",
year = "2019",
month = "2",
day = "6",
doi = "10.1111/1753-6405.12865",
language = "English",
journal = "Australian and New Zealand Journal of Public Health",
issn = "1326-0200",
publisher = "Wiley-Blackwell",

}

“You’ve got to breathe, you know” – asthma patients and carers’ perceptions around purchase and use of asthma preventer medicines. / Davis, Sharon R.; Tudball, Jacqueline; Flynn, Anthony; Lembke, Kirsty; Zwar, Nicholas; Reddel, Helen K.

In: Australian and New Zealand Journal of Public Health, 06.02.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - “You’ve got to breathe, you know” – asthma patients and carers’ perceptions around purchase and use of asthma preventer medicines

AU - Davis, Sharon R.

AU - Tudball, Jacqueline

AU - Flynn, Anthony

AU - Lembke, Kirsty

AU - Zwar, Nicholas

AU - Reddel, Helen K.

PY - 2019/2/6

Y1 - 2019/2/6

N2 - Objective: To explore influences on patients’ purchase and use of asthma preventer medicines and the perceived acceptability of financial incentives via reduced patient co-payments. Methods: Semi-structured telephone or face-to-face interviews were conducted with adults and carers of children with asthma. Interviews were recorded, transcribed verbatim and coded. Data were analysed using thematic analysis via grounded theory. Results: Twenty-four adults and 20 carers for children aged 3–17 years with asthma were interviewed. For medicines choice, most participants did not consider themselves the primary decision-maker; cost of medicines was an issue for some, but effectiveness was described as more important. For adherence, cost, side-effects, perceived benefit and patient behaviours were important. Conclusions: Patient barriers to adherence with asthma preventer medicines including cost are ongoing. Healthcare professionals need to encourage empathic discussion with patients about cost issues. Implications for public health: Asthma patients and carers could benefit from greater involvement and respect within shared decision-making. Healthcare professionals should be aware that cost may be a barrier for patient adherence, and provided with information about the relative costs of guideline-recommended asthma medicines. Patients and healthcare professionals need education around the efficacy of ICS-alone treatment and the rationale behind co-payments, for initiatives around quality use of medicines to succeed.

AB - Objective: To explore influences on patients’ purchase and use of asthma preventer medicines and the perceived acceptability of financial incentives via reduced patient co-payments. Methods: Semi-structured telephone or face-to-face interviews were conducted with adults and carers of children with asthma. Interviews were recorded, transcribed verbatim and coded. Data were analysed using thematic analysis via grounded theory. Results: Twenty-four adults and 20 carers for children aged 3–17 years with asthma were interviewed. For medicines choice, most participants did not consider themselves the primary decision-maker; cost of medicines was an issue for some, but effectiveness was described as more important. For adherence, cost, side-effects, perceived benefit and patient behaviours were important. Conclusions: Patient barriers to adherence with asthma preventer medicines including cost are ongoing. Healthcare professionals need to encourage empathic discussion with patients about cost issues. Implications for public health: Asthma patients and carers could benefit from greater involvement and respect within shared decision-making. Healthcare professionals should be aware that cost may be a barrier for patient adherence, and provided with information about the relative costs of guideline-recommended asthma medicines. Patients and healthcare professionals need education around the efficacy of ICS-alone treatment and the rationale behind co-payments, for initiatives around quality use of medicines to succeed.

UR - http://www.scopus.com/inward/record.url?scp=85061342327&partnerID=8YFLogxK

U2 - 10.1111/1753-6405.12865

DO - 10.1111/1753-6405.12865

M3 - Article

JO - Australian and New Zealand Journal of Public Health

JF - Australian and New Zealand Journal of Public Health

SN - 1326-0200

ER -